Man Group’s Heron Therapeutics HRTX Stock Holding History

Man Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43,000	Closed	-$246K	–	2215
2022 Q1	$246K	Buy	+43,000	New	+$315K	﹤0.01%	1845
2020 Q3	–	Sell	-315,161	Closed	-$4.64M	–	1822
2020 Q2	$4.64M	Buy	+315,161	New	+$5.18M	0.02%	711
2020 Q1	–	Sell	-163,328	Closed	-$3.84M	–	1720
2019 Q4	$3.84M	Buy	+163,328	New	+$3.61M	0.01%	1094
2019 Q3	–	Sell	-29,036	Closed	-$540K	–	1839
2019 Q2	$540K	Sell	29,036 -15,004	-34%	-$300K	﹤0.01%	1657
2019 Q1	$1.08M	Sell	44,040 -16,742	-28%	-$438K	﹤0.01%	1560
2018 Q4	$1.58M	Buy	+60,782	New	+$1.67M	0.01%	1300
2018 Q3	–	Sell	-18,432	Closed	-$716K	–	2144
2018 Q2	$716K	Buy	+18,432	New	+$587K	﹤0.01%	1704

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Man Group's HRTX Position: Q2 2022 in Review

Man Group sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 43,000 shares — an estimated $246K sold.

Man Group first reported a position in HRTX in Q2 2018 and held it in 7 quarters. The position peaked at $4.64M in Q2 2020. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Man Group reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Man Group sold 43,000 Heron Therapeutics shares in Q2 2022, an estimated $246K.
Man Group first reported a position in Heron Therapeutics in Q2 2018 and held it in 7 quarters.
Man Group's Heron Therapeutics position peaked at $4.64M in Q2 2020.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.